COMP <GO>
DVA vs ABBV // FORWARD P/E MULTIPLE
DaVita Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: DVA 7
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: DVA
LAST: $187.50 (-3.01%) • MKT CAP: $12.33B
forward-pe
10.6x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DVA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DVA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 29.00% | +0.20 | DVA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 33.3x | -26.00 | DVA | /valuation <GO> |
| Free Cash Flow Yield | 10.63% | 3.47% | +7.16 | DVA | /fcf-yield <GO> |
| Operating Margin | 15.00% | 24.60% | -9.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.90% | 6.90% | +1.00 | DVA | /net-margins <GO> |
| Revenue Growth (YoY) | 6.50% | 8.60% | -2.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.66 | 5.33 | -3.67 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | DVA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 72.8 | -18.45 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 10.6x | 113.1x | -102.50 | DVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.33B | $513.86B | -$501.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DVA REV | ABBV REV | DVA GROSS % | ABBV GROSS % | DVA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.64B | $61.16B | 44.0% | 70.2% | $1.31B | $17.82B |
| FY 2024 | $12.82B | $56.33B | 44.0% | 70.0% | $1.47B | $17.83B |
| FY 2023 | $12.14B | $54.32B | 44.0% | 44.0% | $1.51B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DVA // BETA 0.95
ABBV // BETA 1.15